Page 5 - Tim Walbert News Today

The Tepezza (teprotumumab-trbw) labeling has been updated to specify for the treatment of thyroid eye disease regardless of TED activity or duration.

The new drug looked so promising — except for that one warning sign.

Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.

Mirum Pharmaceuticals, Inc. today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that... | April 6, 2023

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune's 100 Best Companies to Work For for the third consecutive year. "We are proud to be named to the Fortune

Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses

There’s been a 25 per cent growth rate in the South East’s Foreign Direct Investment (FDI) job numbers over the past five years.

Three years into the great workplace revolution, CEOs and HR leaders are still experimenting and rethinking where—and how—they get things done.